Making a medicine is one of the longest, most expensive, and most failure-prone processes in modern science. From the first spark of an idea to a pill on a pharmacy shelf, the journey typically takes 10 to 15 years and costs a median of $708 million per approved drug. Only about 13% of drugs that enter human testing ever reach the market. Here’s how that process works, step by step.
Finding a Target in the Body
Every medicine starts with a biological target: a specific protein, enzyme, receptor, or gene involved in a disease. Researchers study the biology of a condition to find the molecular “lever” that, if pushed or pulled, could slow, stop, or reverse the disease process. This stage, called target identification and validation, is considered one of the most important decisions in the entire pipeline because everything that follows depends on picking the right target.
Validation means proving the target actually matters. Scientists use lab experiments, genetic studies, and animal models to confirm that interfering with the target changes the course of disease. A poorly validated target can waste years and hundreds of millions of dollars before anyone realizes the approach won’t work in patients.
Discovering a Drug Candidate
Once a target is confirmed, the search begins for a molecule that interacts with it. Pharmaceutical companies screen massive libraries of chemical compounds, sometimes testing hundreds of thousands of molecules in automated systems to find “hits,” compounds that show some activity against the target. These early hits are rough drafts. They might bind weakly, break down too quickly in the body, or cause toxic effects.
Chemists then refine the most promising hits through a process called lead optimization. They systematically tweak the molecule’s structure, adjusting atoms and chemical groups to improve how strongly it binds, how long it lasts in the body, and how safely it behaves. This iterative cycle of design, synthesis, and testing can take two to four years before a single candidate molecule is selected to move forward.
Preclinical Testing
Before any human takes an experimental drug, it must go through extensive preclinical testing. This includes laboratory studies on cells and tissues, followed by studies in animals to evaluate safety, toxicity, and how the drug moves through a living body: how it’s absorbed, distributed, metabolized, and eliminated. Researchers also study what dose range might be effective and what doses cause harm. Regulatory agencies require this safety data before they’ll allow testing in people.
Three Phases of Human Trials
Clinical trials are the proving ground. They unfold in three main phases, each with a different purpose, and most drugs fail somewhere along the way.
Phase 1: Safety
The drug is given to 20 to 100 volunteers, often healthy people, over several months. The primary goal is safety: does the drug cause harmful side effects, and what happens at increasing doses? Researchers also gather early data on how the drug behaves in the human body, including how it’s processed and cleared.
Phase 2: Does It Work?
If Phase 1 goes well, the drug moves to several hundred patients who actually have the disease. These trials last several months to two years and focus on whether the drug produces a real therapeutic benefit. Researchers also continue collecting safety data and refine the optimal dose.
Phase 3: Large-Scale Confirmation
Phase 3 trials enroll 300 to 3,000 patients and run for one to four years. The goal is to confirm the drug works in a large, diverse population and to monitor for adverse reactions that might not have appeared in smaller groups. These are the trials that generate the evidence regulators use to decide whether a drug should be approved.
Regulatory Review and Approval
After successful Phase 3 trials, the drug maker submits a formal application to a regulatory agency like the FDA. This application contains all the data from preclinical and clinical studies, along with detailed information about how the drug is manufactured and labeled. The FDA’s review team then has 6 to 10 months to evaluate the evidence and decide whether to approve the drug. Priority reviews for drugs that address serious conditions can move faster.
Approval isn’t the end of oversight. Regulators can require additional post-market studies (sometimes called Phase 4) to monitor long-term safety once the drug reaches a much larger population.
Making the Active Ingredient
The physical manufacturing of a medicine involves two distinct stages. The first is producing the active pharmaceutical ingredient, the actual molecule that treats the disease. For traditional small-molecule drugs (most pills you’d pick up at a pharmacy), this involves chemical synthesis: raw materials are prepared and fed into reactors where chemical reactions convert them into the target molecule.
The reaction product then goes through recovery, a series of purification steps like distillation, crystallization, filtration, and centrifugation to separate the active ingredient from leftover raw materials, solvents, and byproducts. The purified ingredient is then dried into a powder using specialized equipment like fluid bed dryers or spray dryers.
Biologic medicines, which include treatments like insulin, monoclonal antibodies, and many cancer therapies, are manufactured very differently. Instead of chemical reactions in a flask, biologics are produced by living cells grown in carefully controlled bioreactors. Because proteins have complex surface structures and folding patterns, maintaining consistency from batch to batch is far more difficult than with chemical synthesis. This complexity is a major reason biologics tend to cost more than small-molecule drugs.
Turning the Ingredient Into a Medicine
A pure active ingredient on its own isn’t a usable medicine. It needs to be formulated into a specific dosage form: a tablet, capsule, liquid, injectable, cream, or spray. This is where excipients come in. Excipients are all the inactive ingredients in a finished medicine, and they serve critical roles that go far beyond filler.
Lubricants help tablets release smoothly from manufacturing molds. Binders hold a tablet together so it doesn’t crumble. Coatings protect drugs from being destroyed by stomach acid so they can reach the intestine intact. Surfactants help poorly soluble drugs dissolve in the body. Solubilizing agents like propylene glycol (found in liquid acetaminophen) keep the drug evenly dissolved in liquid formulations. Some excipients even protect the drug from being broken down by digestive enzymes before it can be absorbed. Flavoring and coloring agents make the medicine palatable and identifiable.
The choice of excipients directly affects how well a drug works. They influence how quickly the active ingredient dissolves, how much of it reaches the bloodstream, and how stable the product remains on a shelf over months or years.
Quality Standards in Manufacturing
Pharmaceutical manufacturing facilities must comply with Current Good Manufacturing Practice (CGMP) regulations, enforced in the U.S. by the FDA. These regulations set minimum requirements for the methods, facilities, and controls used in manufacturing, processing, and packaging drugs. They cover everything from building cleanliness and equipment calibration to record-keeping and employee training.
Scaling up production is one of the trickiest parts of manufacturing. A process that works perfectly in a small laboratory flask often behaves differently in a pilot plant or full-scale factory. Crystallization, one of the most critical steps in purifying the active ingredient, is particularly sensitive to scale. Producing a drug with consistent properties across thousands of batches requires careful engineering and constant quality monitoring.
The Cost and Failure Behind Every Medicine
A 2024 analysis published in JAMA Network Open estimated that the median cost to develop a single new drug is $708 million when accounting for the cost of capital and the many failed projects a company runs alongside its successes. The mean cost is even higher at $1.31 billion, pulled up by a small number of extremely expensive outliers. Direct costs alone, without adjusting for failures and capital, come to a median of about $150 million per drug.
Those costs reflect a brutal attrition rate. Of all the drug candidates that enter clinical trials, only about 12.8% ultimately receive marketing approval. The rest fail for lack of efficacy, unacceptable side effects, or commercial reasons. This failure rate hasn’t improved meaningfully in decades, despite advances in technology. It’s the central economic reality of the pharmaceutical industry: the price of every successful drug must cover the cost of many that never made it.